April 29, 2008
Submitted by art on Wed, 2008-04-30 07:27.
GW Pharmaceuticals said in a statement to the stock exchange (regarding recent Sativex trial results) that the patient response rate to its drug was "very high", but the difference from response to a placebo was insufficient so the trial was unable to yield a "statistically significant outcome".
The drug became the first cannabis-derived medicine to win regulatory approval when it was approved in Canada in 2005 as a treatment for pain in multiple sclerosis patients and it is also available in Britain on special prescriptions.